Viking fully enrolls two Phase 3 trials of injectable VK2735
CEO Brian Lian said VANQUISH-1 and VANQUISH-2 will read out in the second half of 2027, with oral Phase 3 starts planned this quarter.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 14 23:01 ETSource: TradingView
The wire
- 01Viking Therapeutics said its GLP-1/GIP dual agonist VK2735 produced 14.7% weight loss at 13 weeks on 15 mg weekly in Phase 2; Phase 3 tests up to 17.5 mg over 78 weeks.
- 02Dosing strategy matters to prescribers: Viking revised titration to start at 1.25 mg after lower nausea rates in patients starting Phase 2 at 2.5 mg rather than 5 mg.
- 03A maintenance study of every-other-week and monthly dosing reports this quarter, but the weekly 17.5 mg arm includes only 15 patients, and oral Phase 3 trails injectable by 12 to 18 months.
From the source
Read at tradingview.comViking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss
Viking Therapeutics VKTX said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13 weeks at the highest tested dose.